Recently, China’s National Medical Products Administration officially approved the combination therapy of Anlotinib Hydrochloride and Penpulimab by Chia Tai Tianqing for the first-line treatment of advanced hepatocellular carcinoma. This marks the tenth approved indication for Anlotinib Hydrochloride, signifying an important innovative option in the field of advanced liver cancer treatment. This therapy is based on a Phase III clinical study published in the internationally renowned oncology journal *The Lancet Oncology*, with its remarkable efficacy data bringing new hope to patients worldwide.
**Research Breakthrough: Significantly Prolongs Survival and Reduces Disease Risk**
The study, named ALTN-AK105-III-02, is a multicenter, randomized, open-label, parallel-controlled Phase III clinical trial designed to evaluate the performance of Anlotinib Hydrochloride combined with Penpulimab versus the traditional standard drug Sorafenib in the first-line treatment of advanced hepatocellular carcinoma. The study enrolled a total of 649 advanced liver cancer patients, of which nearly 41% had macrovascular invasion, and approximately 49.2% had high alpha-fetoprotein levels (≥400 ng/mL). These characteristics typically indicate greater treatment challenges.
The study results are encouraging:
- **Significant Prolongation of Progression-Free Survival:** The median progression-free survival time in the combination therapy group reached 6.9 months, far exceeding the 2.8 months in the control group, with a 47% reduction in the risk of disease progression or death.
- **Noticeable Improvement in Overall Survival:** The median overall survival in the combination therapy group was 16.5 months, compared to 13.2 months in the control group, representing a 31% reduction in the risk of death.
These “dual positive endpoint” data not only demonstrate the advantages of this therapy in delaying disease progression but also show substantial breakthroughs in overall survival benefits, offering more effective treatment options for patients with advanced liver cancer.
**Beijing South Region Oncology Hospital International Department: Your Global Anti-Cancer Partner**
In the face of cancer, timely access to authoritative medical information and professional treatment support is crucial. Beijing South Region Oncology Hospital International Department is dedicated to providing comprehensive oncology diagnosis and treatment services for international patients, including consultations on the latest therapies, personalized treatment planning, and cross-language communication assistance. We collaborate closely with domestic and international research institutions to ensure patients benefit from cutting-edge advancements like the Anlotinib Hydrochloride combination therapy.
**Contact Information: We Are Here to Serve You**
If you or your loved ones are seeking treatment options for advanced liver cancer or other tumors, please contact us immediately through the following methods. Our professional team will provide detailed therapy introductions, medical process guidance, and support for international patients:
- **Phone:** 400-880-3716
Call this number to speak directly with our international patient coordinators for quick consultations and appointment assistance.
- **WeChat:** 17801183037
Add our official WeChat account to receive real-time treatment information, online inquiries, or video consultations.
- **Email:**
① 100085_010@163.com
② myimmnet@163.com
Send medical records or questions to our email, and our expert team will provide personalized treatment recommendations.
**Why Choose Us?**
- **Access to Cutting-Edge Therapies:** We continuously follow global oncology treatment trends to ensure patients have opportunities to receive innovative solutions like the Anlotinib Hydrochloride combination therapy.
- **Multilingual Services:** We offer support in multiple languages, including English, to eliminate communication barriers and ensure a seamless experience for international patients.
- **Comprehensive Assistance:** From visa applications and accommodation arrangements to treatment follow-ups, we provide one-stop attentive services.
Cancer treatment is a race against time. The approval of the Anlotinib Hydrochloride combination therapy has brought new hope to patients with advanced liver cancer. No matter where you are, Beijing South Region Oncology Hospital International Department is ready to be your steadfast partner on your anti-cancer journey. Contact us today to begin your personalized treatment journey!
**Remember Our Contact Information:**
Phone: 400-880-3716
WeChat: 17801183037
Email: 100085_010@163.com or myimmnet@163.com
We look forward to providing you with professional and compassionate medical support!
Post time: Jan-27-2026